ABEONA THERAPEUTICS INC

ABEONASDAQ

🏆 #2362 by market capEarnings Aug 13 · PreUS Equity

$7.40▼ $0.05 (−0.67%)

🌙 After hours$7.40▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 0.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$422M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

51.9%

Healthy

💵FCF Margin

-586.2%

Thin

⚖️P/S Ratio

29.0x

Expensive

Otter Score

Fair

No chart data available for ABEO.

Trading Snapshot

Day Range: $7.32 – $7.48
52-Week Range: $4.00 – $7.65
Volume: $2.70B
Avg Volume: $2.20B
Shares Outstanding: 57.0M
Next Earnings: Oct 14, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $9M
P/E Ratio: 5.8
P/S Ratio: 29.0x
EPS (TTM): $1.17
Dividend Yield: 0.00%

Why Investors Own ABEO

✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▼ −12.6% YoY

Gross Margin (TTM)

33.5%▲ +0.8% YoY

Operating Income (TTM)

$2M▼ −12.6% YoY

Free Cash Flow (TTM)

$2M▼ −12.6% YoY

About ABEONA THERAPEUTICS INC

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

🦦